Literature DB >> 11519054

Differences in stage and therapy for breast cancer across Europe.

M Sant1.   

Abstract

We examined variations in stage, diagnostic workup and therapy for breast cancer across Europe. Seventeen cancer registries in six European countries contributed 4,480 cases diagnosed in 1990-91. The clinical records of these cases were examined, and the distribution of stage, diagnostic examinations and therapy were analyzed. Stage was earliest in the French registries, followed by those of Italy and Eindhoven (Netherlands). The proportion of stage I cancers was highest in the French areas with screening in place. Estonia, the English registries and Granada (Spain) had the most advanced stage at diagnosis. Use of liver ultrasonography varied from 84% (Italian registries) to 18% (Granada). Bone scan use varied from 81% (Italian registries) to 15% (Mersey, UK). The highest proportions treated by breast-conserving surgery were in the French (57%) and English registries (63%); the lowest were in Estonia (6%) and Granada (11%). The highest proportions of Halsted mastectomies were in Italy (19%) and Granada (8%). In all countries except England, 90% of operations included axillary lymphadenectomy. Medical treatment only was given to 8% of (mostly advanced) cases overall. Estonia (21%) and the English registries (14%) had the highest proportions of patients given medication only. Chemotherapy was given to low proportions of node-positive cases in the Italian (76%) and English (74%) areas; breast-conserving surgery for stage I tumors varied from 24% in Granada to 84% in England. These wide differences in breast cancer care across Europe in the early 1990s indicate a need for continual monitoring of past treatments to help ensure application of the most effective protocols. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2001        PMID: 11519054     DOI: 10.1002/ijc.1408

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  Female breast cancer in Gipuzkoa: prognostic factors and survival.

Authors:  N Larrañaga; C Sarasqueta; P Martínez-Camblor; M J Mitxelena; A Mendiola; I Martínez-Pueyo; M Basterretxea
Journal:  Clin Transl Oncol       Date:  2009-02       Impact factor: 3.405

2.  Exclusive and adjuvant radiotherapy in breast cancer patients with synchronous metastases.

Authors:  Romuald Le Scodan; David Ali; Denise Stevens
Journal:  BMC Cancer       Date:  2010-11-17       Impact factor: 4.430

3.  Survival differences between European and US patients with colorectal cancer: role of stage at diagnosis and surgery.

Authors:  L Ciccolallo; R Capocaccia; M P Coleman; F Berrino; J W W Coebergh; R A M Damhuis; J Faivre; C Martinez-Garcia; H Møller; M Ponz de Leon; G Launoy; N Raverdy; E M I Williams; G Gatta
Journal:  Gut       Date:  2005-02       Impact factor: 23.059

4.  Breast cancer patients in Libya: Comparison with European and central African patients.

Authors:  Jamela Mostafa E Boder; Fathi B Elmabrouk Abdalla; Mohamed Ahmed Elfageih; Abuagela Abusaa; Abdelbaset Buhmeida; Yrjö Collan
Journal:  Oncol Lett       Date:  2011-01-20       Impact factor: 2.967

5.  Breast cancer survival in the US and Europe: a CONCORD high-resolution study.

Authors:  Claudia Allemani; Milena Sant; Hannah K Weir; Lisa C Richardson; Paolo Baili; Hans Storm; Sabine Siesling; Ana Torrella-Ramos; Adri C Voogd; Tiiu Aareleid; Eva Ardanaz; Franco Berrino; Magdalena Bielska-Lasota; Susan Bolick; Claudia Cirilli; Marc Colonna; Paolo Contiero; Rosemary Cress; Emanuele Crocetti; John P Fulton; Pascale Grosclaude; Timo Hakulinen; M Isabel Izarzugaza; Per Malmström; Karin Peignaux; Maja Primic-Žakelj; Jadwiga Rachtan; Chakameh Safaei Diba; Maria-José Sánchez; Maria J Schymura; Tiefu Shen; Adele Traina; Laufey Tryggvadottir; Rosario Tumino; Michel Velten; Marina Vercelli; Holly J Wolf; Anne-Sophie Woronoff; Xiaocheng Wu; Michel P Coleman
Journal:  Int J Cancer       Date:  2012-09-18       Impact factor: 7.396

6.  Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data.

Authors:  M P Coleman; D Forman; H Bryant; J Butler; B Rachet; C Maringe; U Nur; E Tracey; M Coory; J Hatcher; C E McGahan; D Turner; L Marrett; M L Gjerstorff; T B Johannesen; J Adolfsson; M Lambe; G Lawrence; D Meechan; E J Morris; R Middleton; J Steward; M A Richards
Journal:  Lancet       Date:  2010-12-21       Impact factor: 79.321

7.  Management of metastatic breast cancer: are we prepared to cope with our own success?

Authors:  A Jimeno; H Cortés-Funes; R Colomer
Journal:  Br J Cancer       Date:  2004-12-13       Impact factor: 7.640

8.  Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer.

Authors:  A M Al Murri; J M S Bartlett; P A Canney; J C Doughty; C Wilson; D C McMillan
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

9.  Diffusion of good practices of care and decline of the association with case volume: the example of breast conserving surgery.

Authors:  Ugo Fedeli; Natalia Alba; Elena Schievano; Cristiana Visentin; Rosalba Rosato; Manuel Zorzi; Giancarlo Ruscitti; Paolo Spolaore
Journal:  BMC Health Serv Res       Date:  2007-10-18       Impact factor: 2.655

10.  Prognostic value of morphology and hormone receptor status in breast cancer - a population-based study.

Authors:  C Allemani; M Sant; F Berrino; T Aareleid; G Chaplain; J W Coebergh; M Colonna; P Contiero; A Danzon; M Federico; L Gafà; P Grosclaude; G Hédelin; J Macè-Lesech; C M Garcia; E Paci; N Raverdy; B Tretarre; E M I Williams
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.